Mesirow Opens Tokyo Office, Signals Japan M&A Push

Mesirow, the Chicago-based independent advisory firm, opened its first Asia-Pacific office this week in Tokyo—marking the latest bet by a US middle-market advisor that Japanese corporates are about to loosen the M&A checkbook. The firm tapped two Japanese deal veterans, Manabu Ogi and Katsuya Fukushima, to lead the new office and build out cross-border transaction capabilities across the region.

The move comes as Japanese companies—flush with record cash reserves but facing demographic headwinds at home—are hunting for growth overseas. At the same time, foreign buyers see undervalued Japanese businesses as acquisition targets, especially in fragmented sectors where consolidation is overdue. Mesirow's timing suggests it believes that middle-market deal flow between the US and Japan is about to accelerate.

Both Ogi and Fukushima bring decades of experience in cross-border M&A. Ogi spent over 20 years at Daiwa Securities, where he advised on transactions across technology, industrials, and consumer sectors. Fukushima comes from SMBC Nikko Securities, where he focused on outbound Japanese acquisitions and inbound investments into Japan. Their combined networks span corporate development teams, financial sponsors, and family offices on both sides of the Pacific.

"We've been watching the Japan market for years," said a Mesirow managing director who asked not to be named. "The question wasn't if we'd open there—it was when, and with whom. These two guys have the relationships and the scar tissue from actually closing deals in this market."

Japan's M&A market has been quietly heating up. According to Refinitiv data, Japanese outbound M&A volume hit $75 billion in 2024, up 18% from the prior year. Inbound deals—foreign buyers acquiring Japanese assets—totaled $32 billion, the highest level since 2019. The drivers are structural: Japan's corporate cash pile now exceeds $3 trillion, yet domestic growth opportunities are scarce in a shrinking market.

The Tokyo Stock Exchange's governance reforms, which began in 2023, have also pushed Japanese boards to deploy capital more aggressively. Companies trading below book value—still roughly 40% of TSE-listed firms—face pressure to buy growth, return cash, or risk activist attention. For many, the path forward involves acquiring technology, talent, or market access abroad.

For US middle-market advisors, Japan represents a large, underserved opportunity. While bulge-bracket banks dominate mega-deals, the sub-$500 million segment remains fragmented and relationship-driven. Western firms that can navigate language barriers, cultural expectations around deal process, and the importance of trust-building—before term sheets—stand to win mandates that pure-play Japanese boutiques can't easily serve.

Mesirow isn't alone in this bet. Harris Williams opened a Tokyo office in 2021. Lincoln International launched one in 2019. Raymond James established a presence in 2022. Each firm saw the same thesis: Japanese corporates need help executing cross-border deals, and the middle market is where most of those deals will happen.

Manabu Ogi's career spans Daiwa Securities' investment banking and M&A advisory divisions, where he worked on over 50 transactions across technology, industrials, and consumer sectors. His client list includes Japanese multinationals executing acquisitions in North America and Europe, as well as foreign strategic buyers entering Japan. He's known for his ability to translate intent across cultures—explaining to a Japanese CEO why a US target's aggressive growth projections aren't fantasy, or helping an American buyer understand why a Japanese seller cares more about employee retention than earnout mechanics.

Katsuya Fukushima spent two decades at SMBC Nikko Securities, most recently leading outbound M&A origination for the firm's corporate clients. His focus areas included healthcare, business services, and software—sectors where Japanese companies have been active acquirers of US and European targets. He's advised on deals ranging from $50 million to $1 billion, with particular expertise in navigating regulatory approvals across CFIUS, Japanese antitrust, and sector-specific clearances.

Together, they give Mesirow something most boutique advisors lack: credibility with both Japanese corporate development teams and US-based financial sponsors. Ogi's Daiwa background signals pedigree to Japanese clients. Fukushima's SMBC Nikko tenure means he already knows the CFOs, CEOs, and board members at mid-cap Japanese firms likely to pursue acquisitions in the next 24 months.

One challenge they'll face: Mesirow is late to the party. Harris Williams, Lincoln, and Raymond James have multi-year head starts in Tokyo. Those firms have already closed marquee deals and built brand recognition among Japanese corporates. Ogi and Fukushima will need to leverage personal relationships to generate early deal flow—because competing on brand alone won't work.

The Tokyo office will focus on three core activities: originating sell-side mandates from Japanese companies divesting non-core assets, advising Japanese corporates on US and European acquisitions, and representing US middle-market firms seeking Japanese buyers. That last category is less obvious but potentially lucrative—Japanese corporates often overpay for US assets because they lack local market intelligence and rely on intermediaries to source deals.

Mesirow enters a market where several US boutiques have already staked claims. Harris Williams' Tokyo office, opened in 2021, has closed over a dozen cross-border deals, including advising Japanese healthcare companies on US acquisitions and representing US software firms in sales to Japanese strategics. The firm staffed its office with former Morgan Stanley and Nomura bankers, emphasizing sector expertise over pure relationship coverage.

Lincoln International took a different approach. Its Tokyo office, launched in 2019, focuses heavily on private equity—advising Japanese PE funds on acquisitions and exits, and helping US funds source co-investment opportunities in Japan. Lincoln's model assumes that Japanese PE, though still nascent compared to the US, will drive deal activity over the next decade as family-owned businesses seek succession solutions.

Raymond James opened its Tokyo office in 2022 with a mandate to serve Japanese corporates pursuing acquisitions in the US energy and industrials sectors. The firm believed that Japan's push toward energy security and supply chain resilience post-COVID would drive M&A activity—a thesis that's played out in deals like Japanese trading houses acquiring US LNG infrastructure and renewable energy platforms.

Then there are the Japanese domestic players: Nomura, Daiwa, SMBC Nikko, and Mizuho. These firms dominate large-cap advisory but often struggle in the middle market, where speed, sector expertise, and willingness to take small mandates matter more than balance sheet size. That's the wedge Mesirow and its peers are exploiting.

But here's the wrinkle: Japanese domestic boutiques are also proliferating. Firms like GCA, Plutus Consulting, and Frontier Management have built middle-market M&A practices that combine local market knowledge with leaner cost structures than the bulge bracket. These firms don't have Mesirow's US origination capabilities, but they're faster, cheaper, and better-connected domestically. The competitive threat cuts both ways.

Anyone who's closed a US-Japan deal will tell you: the mechanics are brutal. Timelines stretch because Japanese buyers expect months-long exclusivity periods before signing an LOI—something US sellers loathe. Valuation expectations diverge because Japanese corporates often justify acquisitions based on strategic synergies that Western analysts dismiss as fictional. And deal certainty suffers because Japanese boards move slowly, consensus-driven decision-making can derail transactions late, and earnouts are culturally uncomfortable.

Then there's CFIUS. Japanese buyers face less scrutiny than Chinese acquirers, but sensitive sectors—semiconductors, defense contractors, critical infrastructure—still trigger reviews. Deals can take 12-18 months to close when regulatory approvals stack up across Japan's Fair Trade Commission, US antitrust, and CFIUS. Advisors who can't navigate that complexity lose mandates.

Mesirow's bet is that middle-market M&A—deals between $50 million and $500 million—will outpace mega-deals in US-Japan cross-border activity over the next five years. The logic: Japanese corporates are risk-averse, and smaller acquisitions allow them to test new markets without betting the company. Meanwhile, US middle-market firms with strong technology, brands, or market positions are undervalued relative to public comps—making them attractive targets for Japanese cash.

Look at recent deal activity and the thesis holds. Japanese buyers have acquired US middle-market software companies (Asteria acquiring Handbook, DMM.com buying multiple SaaS firms), healthcare services platforms (Japanese PE buying US dental and veterinary roll-ups), and industrial automation businesses (Japanese manufacturers consolidating fragmented US suppliers). These aren't headline-grabbing mega-deals, but they're consistent, repeatable, and margin-rich for advisors.

The flip side: sell-side mandates from Japanese companies divesting non-core assets. Japan's corporate restructuring wave—driven by TSE governance reforms and activist pressure—is creating a steady flow of carve-outs and divestitures. These assets often lack obvious domestic buyers, making cross-border sales the default exit. US private equity funds and strategics are willing buyers, but they need advisors who can explain why a sleepy Japanese industrial component maker is actually worth buying.

Mesirow has built its US business around exactly this kind of work: advising founder-owned businesses, corporate carve-outs, and mid-cap companies on sales, recapitalizations, and buy-side mandates. The Tokyo office extends that playbook to Japan—if Ogi and Fukushima can convince Japanese clients that Mesirow understands their market as well as US buyers.

Three sectors stand out as likely near-term focus areas for Mesirow's Tokyo office. First, healthcare services—where Japanese companies see US platforms in dental, veterinary, home health, and behavioral health as models for addressing Japan's aging population crisis. Second, industrial automation and robotics—where Japanese manufacturers are acquiring US software and AI companies to digitize legacy operations. Third, consumer brands—where Japanese corporates hunt niche US brands with pricing power and digital distribution, betting they can scale them in Asia.

Energy and infrastructure are wild cards. Japanese trading houses (Mitsubishi, Mitsui, Sumitomo) are actively buying US energy assets, but those deals skew larger and are typically handled by bulge-bracket banks. The middle-market opportunity exists in renewable energy—solar developers, EV charging networks, battery storage platforms—where Japanese corporates want exposure but lack internal expertise.

For Mesirow, success in Tokyo means closing 3-5 cross-border transactions in year one and building a pipeline of recurring clients—Japanese corporates that return for multiple deals and US clients that view the Tokyo office as a credible sourcing channel for Japanese buyers. Revenue isn't the only metric; brand-building in a new market where Mesirow has zero name recognition matters as much.

Failure scenarios are straightforward. If Ogi and Fukushima can't generate deal flow in the first 12 months, the office becomes a cost center that's hard to justify. If early deals fall apart late in process—common in cross-border M&A—clients lose confidence. If Mesirow's US teams don't feed the Tokyo office with sell-side mandates that need Japanese buyers, the office becomes isolated and ineffective.

The other risk: talent retention. Both Ogi and Fukushima left established Japanese institutions to join a US boutique with no local brand. If they don't see early wins, or if Mesirow's compensation structure doesn't match their expectations, they could depart—leaving the office hollow. Tokyo M&A is relationship-driven, and relationships walk out the door when senior bankers leave.

One thing working in Mesirow's favor: the firm is independent and employee-owned, which gives it flexibility that publicly traded competitors lack. It can invest in Tokyo for the long haul without quarterly earnings pressure. But independence also means limited capital for expensive hires, marketing, or deal losses. Ogi and Fukushima will need to be self-sufficient quickly.

Mesirow operates across investment banking, asset management, and wealth advisory, with over $300 billion in assets under administration and roughly 1,400 employees. The firm's M&A advisory practice has historically focused on middle-market deals in the US across industrials, business services, healthcare, and consumer sectors. Tokyo represents the firm's first major international expansion in advisory—a bet that cross-border deal flow will become a larger share of middle-market M&A over the next decade.

The move also reflects a broader industry trend: US boutique investment banks are globalizing. Houlihan Lokey operates in over 20 countries. Evercore has offices across Europe and Asia. Jefferies built a global platform through acquisitions. Mesirow is smaller and later to the game, but the logic is the same—clients increasingly expect advisors to source buyers and sellers globally, not just domestically.

Tokyo is unlikely to be Mesirow's last international office. Europe—particularly Germany and the UK—would be logical next steps if the Japan experiment works. But the firm is deliberate, not aggressive, in its expansion pace. It opened its first office outside Chicago (in New York) only a decade ago. Tokyo signals ambition, but not recklessness.

The test will be whether Mesirow can leverage its US platform to feed the Tokyo office with deal flow—and vice versa. If the Tokyo team becomes a standalone operation that doesn't integrate with the rest of the firm, the strategic rationale weakens. The best-case outcome: Ogi and Fukushima become internal champions who teach Mesirow's US bankers how to think about Japanese buyers, while simultaneously educating Japanese clients about the US middle market.

Ogi and Fukushima will spend Q1 2025 building out the office infrastructure—hiring analysts, setting up compliance and legal frameworks, and conducting pitch meetings with prospective clients. Expect their first mandates to come from existing relationships: companies they've advised in prior roles who trust them enough to follow them to a new firm.

By mid-2025, the office should announce its first deal—likely a sub-$100 million transaction where Mesirow represented either a Japanese buyer acquiring a US target or a US seller finding a Japanese acquirer. That deal matters less for its economics than for its signaling value: proof that Mesirow can execute in this market.

The real inflection point comes in 2026. By then, the Tokyo office will either have established a recurring pipeline of mandates and built credibility with Japanese corporates—or it will be struggling to justify its existence. The difference will come down to whether Ogi and Fukushima can translate relationships into closed deals, and whether Mesirow's US platform feeds the Tokyo office with opportunities it couldn't generate alone.

One wildcard: macroeconomic conditions. If the yen weakens further, Japanese outbound M&A becomes more expensive. If US-China tensions escalate, Japanese corporates may slow acquisitions in politically sensitive sectors. If a US recession hits, middle-market deal activity dries up—taking Mesirow's entire thesis with it. But if the structural drivers hold—Japanese corporate cash, TSE governance reforms, demographic decline, and undervalued US middle-market assets—the opportunity is real.

For now, Mesirow's Tokyo bet is exactly that: a bet. It's early, the competition is entrenched, and the market is unforgiving of firms that can't deliver. But Ogi and Fukushima have the credentials, the relationships, and—crucially—the incentive to make it work. Whether they do will determine if Mesirow's Asia-Pacific ambitions stay in Tokyo or expand across the region.